Medynus Inc. – Trademark Portfolio
Entity Type: 03
Medynus Inc. owns a portfolio of 10 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), including well-known marks such as GOBLIN, IMPEACE, and MEDYNUS. Of these, 3 are registered and 7 are pending. The portfolio spans 5 Nice Classification classes, led by Class 10 (Medical Apparatus) and Class 42 (Computer & Scientific). Headquartered in Irvine, CA.
18 Technology Dr
Suite 109
Irvine, CA 92618
Showing of trademarks Trademarks
Trademark Classifications
Medynus Inc.'s trademark portfolio spans 5 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Advertising; business management; business administration; office functions
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does Medynus Inc. have?
Medynus Inc. has 10 U.S. trademarks filed with the USPTO. Of these, 3 registered, 7 pending.
What trademark classes does Medynus Inc. file in?
Medynus Inc. files trademarks across 5 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 9 (Computers & Electronics), Class 35 (Advertising & Business), Class 44 (Medical Services). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.
What are Medynus Inc.'s most well-known trademarks?
Medynus Inc.'s registered trademark portfolio includes well-known marks such as GOBLIN, IMPEACE, and MEDYNUS. These are among 3 currently registered trademarks in the portfolio.
What is Medynus Inc.'s trademark registration success rate?
Medynus Inc. has a 100% trademark registration rate, with 3 out of 3 resolved applications resulting in successful registration. Currently, 7 applications are pending review.